Japanese drugmaker Daiichi Sankyo's share price has risen fivefold since 2017, thanks to the successful launch of its breast cancer drug Enhertu, which has the potential to replace chemotherapy. Group president Hiroyuki Okuzawa looks back on this success and discusses the positive study results for its other cancer drugs. He also discusses the integration of AI into the company's research and manufacturing activities, and the potential of using this technology to save labor and focus on more productive tasks.
(MT Newswires)
